Moderna shares jump as stock buying pressure builds

Traders Union
All News
Financial News
Moderna rises 2.78% today to $46.99

Highlights

Moderna President Stephen Hoge exercised options and sold 53,336 shares at $48.40, signaling possible executive caution.
A peer-reviewed study found Moderna's mRNA-1273 vaccine 75.5% effective against moderate to severe COVID-19 in Taiwanese children aged 6 to 11 during the Omicron wave.
Moderna trades below key moving averages amid bearish momentum, but oversold signals point to a high probability of a rebound to the $44.89–$48.39 range.

Share sales and clinical updates influence sentiment amid regulatory focus

On May 15, 2026, President Stephen Hoge exercised options and sold 53,336 shares of Moderna at $48.40 per share. A recent peer-reviewed study reported that Moderna's mRNA-1273 COVID-19 vaccine was approximately 75.5% effective against moderate to severe COVID-19 in Taiwanese children aged 6 to 11 during the Omicron BA.2/BA.5 period. Investors are also closely monitoring regulatory milestones and updates to Moderna's mRNA pipeline.

Anton Kharitonov, expert at Traders Union, sees persistent bearish momentum in Moderna's price action. He points out that the stock trades below both the 20-day and 50-day moving averages, showing technical weakness. Weak momentum indicators and negative Bull/Bear Power confirm that sellers still control the intraday action. Even positive vaccine study results and insider activity were not enough to reverse negative sentiment. "With sellers exhausted but not defeated, I remain skeptical of any sustained rebound until the price reclaims key moving averages," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, notes that Moderna retains upside potential despite recent volatility. He highlights robust weekly buy signals and a strong price reaction following positive news on pediatric vaccine efficacy. Investors should pay close attention to upcoming regulatory catalysts and the expanding mRNA pipeline. The bullish structure remains intact as long as support above $44.89 holds. "Moderna's long-term growth story is reinforced by positive momentum and scientific progress — further gains look increasingly likely in the short term," says Karapetjanc.

Jainam Mehta, market strategist, believes Moderna is trading at a key technical inflection. He sees short-term oversold readings and day-end strength as possible signals for a bounce, but lingering bearish momentum could limit gains. Weekly indicators argue for a tactical trade towards $48.39 if support holds. "I would watch for a potential breakout above resistance, but caution is warranted until bullish confirmation appears on higher timeframes," says Mehta.

Mixed indicators and oversold signals point to potential rebound risk

Momentum indicators show mixed signals: the MACD remains negative, pointing to lingering bearish sentiment, and the ADX indicates a weak general trend. The RSI, Stochastic RSI, and CCI show the stock is oversold on the daily timeframe, suggesting a rising risk of a short-term rebound. Bull/Bear Power (BBP) remains deeply negative at -1.81, confirming sellers still dominate intraday action, and the oversold forecast further affirms exhaustion among sellers. After opening with an upside gap of about $0.28, Moderna is up 2.78% on the day at $46.99, trading in the upper part of the intraday range as volatility stands at 3.04%. The overall tone is one of strength toward session highs, but bearish momentum still lingers.

Previously it was reported that, despite ongoing short-term pressures, Moderna was supported by constructive regulatory developments and positive clinical data, suggesting potential for sentiment shifts upon key technical breaks. The current analysis strengthens this outlook by highlighting fresh momentum from oversold conditions and recent positive trial results, positioning a breakout above $48.39 as the critical level that could catalyze renewed upside in the near term.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.